ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $3.51M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
165% more call options, than puts
Call options by funds: $560K | Put options by funds: $211K
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.01% less ownership
Funds ownership: 2.77% → 1.76% (-1%)
51% less capital invested
Capital invested by funds: $7.11M → $3.51M (-$3.6M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$1.52M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$352K |
| 3 |
VF
Virtu Financial
New York
|
+$337K |
| 4 |
HF
HRT Financial
New York
|
+$242K |
| 5 |
Morgan Stanley
New York
|
+$6.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$3.45M |
| 2 |
Jane Street
New York
|
-$979K |
| 3 |
GCM
Gunderson Capital Management
Mt. Pleasant,
South Carolina
|
-$918K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$72.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$19.6K |
BIS Hedge Fund Activity: Q1 2019 in Review
8 of the 4,632 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2019, worth a combined $3.51M — down 51% from $7.11M a quarter earlier.
Fund positioning in BIS was balanced in Q1 2019: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was WealthSource Partners, opening a new position worth an estimated $1.52M. The largest seller was Healthcare Value Capital, exiting entirely with an estimated $3.45M sold.
- 8 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $3.51M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2019, down 51% quarter-over-quarter.
- 3 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2019 and 3 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2019 was WealthSource Partners, an estimated $1.52M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2019 was Healthcare Value Capital, an estimated $3.45M sold.
Based on aggregated 13F filings for Q1 2019.